Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (61-70 of 350) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|July 2, 2018
[What role for the direct oral anticoagulants in oncology?]Loïc Lebellec, Claude Kouakam, Nicolas Bertrand, et al.
Critical Reviews in Oncology/Hematology|November 12, 2015
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trialsAgnès Ducoulombier, Sophie Cousin, Nuria Kotecki, et al.
Psycho-Oncology|December 4, 2015
Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative careTanguy Leroy, Emmanuelle Fournier, Nicolas Penel, et al.
Palliative & Supportive Care|June 28, 2018
"Impossible" patients in oncology: Two unusual casesMichel Reich, Williams Tessier, Justine Lemaire, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025Nicolas Penel, Axel Le Cesne, Jean-Yves Blay
Contemporary Clinical Trials|February 28, 2012
Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year periodStéphanie Clisant, Aurélie Clermont, Antoine Adenis, et al.
Bulletin Du Cancer|July 30, 2004
[A prospective evaluation of antibiotic prophylaxis efficacy for breast cancer surgery following previous chemotherapy]Nicolas Penel, Charles Fournier, Sylvia Giard, et al.
Investigational New Drugs|July 10, 2010
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugsNicolas Penel, Antoine Adenis, Stéphanie Clisant, et al.
Critical Reviews in Oncology/Hematology|May 28, 2013
Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survivalNicolas Penel, Sophie Cousin, Alain Duhamel, et al.
BMC Cancer|August 26, 2016
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordomaJuliette Eroukhmanoff, Frederic Castinetti, Nicolas Penel, et al.
Pageof 35

Showing results (61-70 of 350) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|July 2, 2018
[What role for the direct oral anticoagulants in oncology?]Loïc Lebellec, Claude Kouakam, Nicolas Bertrand, et al.
Critical Reviews in Oncology/Hematology|November 12, 2015
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trialsAgnès Ducoulombier, Sophie Cousin, Nuria Kotecki, et al.
Psycho-Oncology|December 4, 2015
Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative careTanguy Leroy, Emmanuelle Fournier, Nicolas Penel, et al.
Palliative & Supportive Care|June 28, 2018
"Impossible" patients in oncology: Two unusual casesMichel Reich, Williams Tessier, Justine Lemaire, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025Nicolas Penel, Axel Le Cesne, Jean-Yves Blay
Contemporary Clinical Trials|February 28, 2012
Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year periodStéphanie Clisant, Aurélie Clermont, Antoine Adenis, et al.
Bulletin Du Cancer|July 30, 2004
[A prospective evaluation of antibiotic prophylaxis efficacy for breast cancer surgery following previous chemotherapy]Nicolas Penel, Charles Fournier, Sylvia Giard, et al.
Investigational New Drugs|July 10, 2010
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugsNicolas Penel, Antoine Adenis, Stéphanie Clisant, et al.
Critical Reviews in Oncology/Hematology|May 28, 2013
Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survivalNicolas Penel, Sophie Cousin, Alain Duhamel, et al.
BMC Cancer|August 26, 2016
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordomaJuliette Eroukhmanoff, Frederic Castinetti, Nicolas Penel, et al.
Pageof 35